Cross neutralization of emerging SARS-CoV-2 variants of concern by antibodies targeting distinct epitopes on spike
Journal article published in 2021 by
Siriruk Changrob 
,
Yanbin Fu ,
Jenna J. Guthmiller ,
Peter J. Halfmann ,
Lei Li ,
Christopher T. Stamper,
Haley L. Dugan,
Molly Accola,
William Rehrauer,
Nai-Ying Zheng,
Min Huang,
Jiaolong Wang,
Patrick C. Wilson ,
Steven A. Erickson,
Henry A. Utset
and other authors.
,
Yanbin Fu ,
Jenna J. Guthmiller ,
Peter J. Halfmann ,
Lei Li ,
Christopher T. Stamper,
Haley L. Dugan,
Molly Accola,
William Rehrauer,
Nai-Ying Zheng,
Min Huang,
Jiaolong Wang,
Patrick C. Wilson ,
Steven A. Erickson,
Henry A. Utset
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Data provided by 
Abstract
We describe the binding and neutralization properties of a new set of human monoclonal antibodies derived from memory B cells of 10 coronavirus disease 2019 (COVID-19) convalescent donors in the first pandemic wave of prototype SARS-CoV-2. There were 12 antibodies targeting distinct epitopes on spike, including two sites on the RBD and one on the N-terminal domain (NTD), that displayed cross-neutralization of VOCs, for which distinct antibody targets could neutralize discrete variants.